| Tolicizumab研究进展 |
| |
| 引用本文： | 陶可,熊奡,曾晖.Tolicizumab研究进展[J].国际免疫学杂志,2011,34(5):264-269. |
| |
| 作者姓名： | 陶可 熊奡 曾晖 |
| |
| 作者单位： | 北京大学深圳医院骨关节科,深圳,518036 |
| |
| 摘 要： | 类风湿关节炎（RA）、幼年特发性全身性关节炎（sJIA）、Castleman病等多种炎性疾病发生、进展过程中均有IL-6的过量表达，且发挥关键作用。Tolicizumab是第一个人源性的IL-6R抗体，通过特异性识别结合IL-6R而阻断IL-6生物学活性，发挥抑制上述疾病炎症反应的作用。大量研究结果证实。Tocilizumab不仅能明显缓解RA的临床症状，而且能防止关节继续被破坏。此外，Tocilizumab在治疗全身性和关节型sJIA、Castleman病等疾病也获得了巨大的成功。
|
| 关 键 词： | Tolicizumab IL-6 类风湿关节炎 幼年特发性全身性关节炎 Castleman病interleukin |
Research advance of Tolicizumab |
| |
| TAO Ke,XIONG Ao,ZENG Hui.Research advance of Tolicizumab[J].International Journal of Immunology,2011,34(5):264-269. |
| |
| Authors: | TAO Ke XIONG Ao ZENG Hui |
| |
| Institution: | (Department of orthopaedics of Pe-king University Shenzhen Hospital, Shenzhen 518036, China) |
| |
| Abstract: | Over-production of IL-6 plays an essential role in autoimmune diseases such as rheumatoid arthritis(RA)and juvenile idiopathic arthritis(JIA). Tocilizumab, the first humanized anti-human IL-6 receptor antibody, can bind IL-6R by specific recognition and subsequently block the biological activity of IL-6.A large number of studies have demonstrated that tocilizumab was effective not only in improving clinical man-festation but also in preventing joint destruction of RA. In addition, A great successs has been made in the treatment of systemic and articular types of JIA, Castleman's disease, etc, by the application of tolicizubmab. |
| |
| Keywords: | Tolicizumab Interleukin-6 Systemic juvenile idiopathic arthritis |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
